Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Administration of rivoceranib is continued until disease progression, occurrence of intolerable toxicity, failure to achieve morphologic leukemia-free state after 4 cycles of treat···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：63
The recommended dosage of Revuforj varies according to the patient's body weight and concomitant use of strong CYP3A4 inhibitors.Administration of RevuforjFor patients aged 1 y···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：59
Take Revuforj exactly as directed by your healthcare provider. Do not change your dose or stop taking Revuforj unless your healthcare provider tells you to do so.What is the recomm···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：68
Your doctor may prescribe Revuforj tablets in multiple dosage strengths, and it is crucial that you understand how to take the medication correctly. Be sure to know the exact numbe···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：52
Revumenib is a menin inhibitor that blocks the interaction between wild-type lysine methyltransferase 2A (KMT2A), KMT2A fusion proteins and menin.What is the indication for Revufor···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：55
Revuforj tablets are available in different dosage strengths, each corresponding to a distinct color.Latest 2026 Pricing for Revuforj (Ruimeini)Revuforj, a pharmaceutical product r···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：63
Revuforj is typically indicated for the treatment of patients with specific types of acute leukemia.What is the approximate price of one box of Revuforj?Revuforj manufactured by Lu···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：69
On June 24, 2025, Syndax Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the supplemental New Drug Application (sNDA) for ···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：63
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy originating from B-lineage or T-lineage lymphoid cells. Most adult ALL cases have an acute onset, with fever, bleedin···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：48
Recently, Syndax Pharmaceuticals announced additional positive data from the AUGMENT-101 trial of Revuforj (revumenib) in patients with relapsed or refractory (R/R) nucleophosmin 1···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：49
Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor, primarily indicated for the treatment of ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSC···【more】
Article source：Captain MedicineRelease date：2026-01-27Recommended：46
Lorlatinib is a third-generation targeted therapy indicated for ALK-positive metastatic non-small cell lung cancer (NSCLC), primarily used in patients who have developed resistance···【more】
Article source：Captain MedicineRelease date：2026-01-26Recommended：37
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1552025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1732025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1882025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1682025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1642025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
